Home > Result Summaries: Compounds > GSK576389A

Result Summaries: GSK576389A

GSK Study ID	Phase	Title	Summary (Download)
103304_1	phase 1	Study in an elderly population aged over 65 years (>= 65 years-old) in order to evaluate reactogenicity and immunogenicity of GSK Bio’s experimental Influenza vaccines, administered intramuscularly as compared to Fluarix vaccine (0 citation(s))
104540_1	phase 1	A phase I/II, open, controlled study in order to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals influenza candidate adjuvanted vaccine in an elderly population aged over 65 years previously vaccinated in 2004 with the same candidate vaccine (0 citation(s))
104886_1	phase 2	Demonstrate the non inferiority in term of cellular mediated immune response of GSK Biologicals influenza candidate vaccines containing various adjuvants administered in elderly population (aged 65 y & older) vs Fluarix™ (known as alpha-Rix™ in Belgium) administered in adults (18-40 y) (5 citation(s))
104887_1	phase 2	Evaluate reactogenicity & immunogenicity of adjuvanted influenza vaccine in elderly adults previously vaccinated with the same candidate vaccine. Fluarix™ administered in young & elderly adults will be used as reference (0 citation(s))
104888_1	phase 2	A phase II/III, observer-blind, Multi-Country, Multi-Centre, randomized study to demonstrate the superiority in terms of immunogenicity of adjuvanted influenza vaccine administered in adults aged 50 years and older compared to Fluarix™ (0 citation(s))
109821_1	phase 3	Observer blind study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals influenza vaccine GSK576389A administered to adults over 65 years previously vaccinated with the same vaccine, compared to Fluarix™ (0 citation(s))
110223_1	phase 2	Reactogenicity and immunogenicity of GSK Biologicals influenza vaccine GSK576389A in elderly adults (≥67 years) previously vaccinated with the same candidate vaccine. Fluarix™ will be used as reference (0 citation(s))
110263_1	phase 2	Reactogenicity and immunogenicity of GSK Biologicals' influenza vaccine GSK576389A in elderly adults (≥66 years) previously vaccinated with the same candidate vaccine. Fluarix™ will be used as reference (0 citation(s))
110620_1	phase 2	Non-Inferiority of GlaxoSmithKline Biologicals' Influenza Vaccine (GSK576389A) 1 Container Over 2 Container Presentation in Adults Aged 65 Years and Over (0 citation(s))
110847_1	phase 2	Observer blind immunogenicity and safety study of GlaxoSmithKline Biologicals' influenza vaccine GSK576389A with various formulations in adults aged 65 years and above (0 citation(s))
111454	phase 2	Non-inferiority study of GlaxoSmithKline Biologicals' influenza vaccine GSK576389A using different formulations. (0 citation(s))